Midatech Pharma   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cardiff United Kingdom (2000)

Organization Overview

First Clinical Trial
2018
NCT03490396
First Marketed Drug
2005
tamoxifen (nolvadex)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

FORTOVIA | Midatech Pharma | MIDATECH PHARMA US | Midatech Pharma US Inc.

Active Ingredients

Marketed Drugs (3)

miconazole (monistat) (2010)

ondansetron (zofran) (2010)

tamoxifen (nolvadex) (2005)

Drugs in Phase 4 Trials (5)

aluminum hydroxide (Gaviscon) (1 trial)

diphenhydramine (benadryl) (1 trial)

lidocaine (xylocaine) (1 trial)

magnesium hydroxide (1 trial)

simethicone (1 trial)

Drugs in Phase 3 Trials (3)

Key: Midatech Pharma (0) Acquired (3)

docetaxel (taxotere) (2 trials)

pemetrexed (alimta) (1 trial)

talabostat (7 trials)

Drugs in Phase 2 Trials (5)

Key: Midatech Pharma (1) Acquired (4)

cisplatin (platinol) (1 trial)

gemcitabine (gemzar) (1 trial)

krn 5500 (1 trial)

panobinostat (farydak) (3 trials)

rituximab (rituxan) (1 trial)

Drugs in Phase 1 Trials (1)

gadolinium (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioma (Phase 2)

Medulloblastoma (Phase 1)

Mucositis (Phase 4)

Stomatitis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 14